Autres langues Sensorion

Actions

ALSEN

FR0012596468

Recherche biotechnologique et médicale

Marché Fermé - Euronext Paris 17:55:00 07/09/2026			Après clôture 21:50:28
0,2500 ^EUR	+0,60%		0,2500	0,00%

03/09	Sensorion reçoit l'autorisation de l'ANSM pour lancer l'essai clinique de phase I/II SENS-601 dans la perte auditive liée au gène GJB2	CI
03/09	Sensorion obtient le feu vert en France pour l'essai clinique de son principal candidat de thérapie génique contre la perte auditive	MT

Autres langues

03/09	Sensorion Receives Clinical Trial Authorization in France for SENS-601 Gene Therapy for Gjb2-Related Hearing Loss
03/09	Sensorion Gets Go-ahead in France for Trial of Lead Gene Therapy Candidate for Hearing Loss
03/09	Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
29/07	Sensorion Announces a Reverse Share Split of its Shares
10/06	Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
10/06	Sensorion Applies for Clinical Trial in Canada, France for SENS-601
10/06	Sensorion Achieves Key Regulatory Milestones for SENS-601 for GJB2-related Hearing Loss and Selects Program as Lead Gene Therapy Candidate
18/05	French Biotech Company Sensorion Names New CEO
18/05	Sensorion : Inside Information / Other news releases
18/05	Sensorion Appoints Fred Chereau as Chief Executive Officer
18/05	Sensorion SA Announces Chief Executive Officer Changes
18/05	Sensorion SA Announces Resignation of Géraldine Honnet as Chief Medical Officer
13/05	Sensorion : Inside Information / Other news releases
13/05	Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
05/05	Sensorion Announces its Participation in the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
01/05	Certain Ordinary Shares of Sensorion SA are subject to a Lock-Up Agreement Ending on 1-MAY-2026.
22/04	Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 11, 2026
21/04	Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 11, 2026
23/03	Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development
23/03	Sensorion : Inside Information / Other news releases
23/03	Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-in-Human Clinical Development
18/03	Sensorion : Inside Information / News release on accounts, results
18/03	Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report
18/03	Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2025
17/02	Sensorion Announces CEO Transition